January 18, 2011 — Exemestane used alone for 5 years is similar to exemestane used after 2 to 3 years of tamoxifen in the prevention of relapse in postmenopausal women with hormone-responsive early ...

Please provide your email address to receive an email when new articles are posted on . Adjuvant therapy with exemestane was safer and more effective than tamoxifen in reducing breast cancer ...

February 6, 2012 — New data from a subset of postmenopausal women participating in a landmark trial that established exemestane for the prevention of breast cancer show that the drug significantly ...

Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, ...

Please provide your email address to receive an email when new articles are posted on . Everolimus plus exemestane resulted in a greater PFS benefit versus everolimus alone in patients with estrogen ...

BRUSSELS, BELGIUM (September 19, 2003) - A study published in the September 2003 issue of Annals of Oncology (vol. 14, issue 9) indicated that exemestane demonstrates a high response rate for ...

Selective estrogen-receptor modulators (tamoxifen [Nolvadex, Soltamox], raloxifene [Evista]) have been shown to reduce the risk of breast cancer in postmenopausal women, but also have been associated ...

Tamoxifen is an estrogen-receptor (ER) antagonist blocking the action of estrogen. The risk–benefit ratio of using tamoxifen for longer than 5 years in the adjuvant setting is still unclear. Aromatase ...

Adjuvant breast cancer treatments often act by reducing circulating estrogen levels or inhibiting estrogen receptor action. Preclinical studies have suggested that exemestane, which acts by ...